Diagnostics Without Blind Spots
Read this exciting story from Los Angeles Times October 23, 2026 issue. Seegene is building a more comprehensive model for molecular diagnostics, combining high-multiplex syndromic PCR, automation and real-world data to broaden access to more comprehensive molecular testing worldwide. Seegene, a South Korean biotechnology company, is building a more comprehensive model for molecular diagnostics, combining high-multiplex syndromic PCR, automation and real-world data to expand access to more comprehensive molecular testing worldwide. The Global Million Clinical Study (GMCS) aims to gather real-life evidence from one million test cases and assess the clinical utility of comprehensive syndromer PCR testing across respiratory, gastrointestinal and reproductive-tract infections. The project represents a larger than another clinical program and aims to drive a paradigm shift in molecular diagnostic.
公開済み : 昨日 沿って の Health Tech Science
Seegene is building a more comprehensive model for molecular diagnostics, combining high-multiplex syndromic PCR, automation and real-world data to broaden access to more comprehensive molecular testi... [1912 symbols]
